Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of death compared to MabThe...
Amgen, announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with ...
Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced a collaboration with the National Cancer Institu...
Cellistic, a pioneer in induced pluripotent stem cells (iPSC)-based cell therapies, is launching the Echo™-NK platform to enable the scalable manuf...
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) plus Yervoy®...
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been approved in the European Union (EU) for the treatment of adult...
Pillar Biosciences, Inc., the leader in Decision Medicine™, announced they have received nationwide Medicare coverage by the Centers fo...
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment o...
Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a...
Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) for patients with pro...
Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the trea...
Exelixis, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the tre...
Merck known as MSD outside of the United States and Canada, announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, evaluating the ...
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight ca...
© 2025 Biopharma Boardroom. All Rights Reserved.
